Medhya rasayana restores memory function against doxorubicin-induced cognitive decline: Possibly by its neuroprotective effect

Karthik Gourishetti, Sawan Ghetia, Ligin Jacob, Sanchari Basu Mallik, Pawan Ganesh Nayak, Anoop Kishore, Krishnadas Nandakumar, Sulaiman Mohammed Alnaseer, Shalam Mohamed Hussain

Research output: Contribution to journalArticle

Abstract

Background: Medhya Rasayana (MR) is an ayurvedic formulation used to rejuvenate the intellectual functions. It was shown to improve the cognitive function in rats. Hence, the present study was designed to study the neuroprotective effect of MR against Doxorubicin (DOX)-induced cognitive deficits which usually occurs in long-term breast cancer survivors. Methods: The neuroprotective effect of MR was studied in-vitro using IMR-32 cell lines against DOX-induced toxicity while the protective effect of MR against DOX-induced cognitive dysfunction was evaluated in Novel object recognition task (NORT) assay in rats. Results: In IMR-32 cell line, DOX (100 nM) treatment reduced the cell viability and arrested the cell cycle at G2/M phase. Pre-treatment with MR significantly prevented the DOX-induced cytotoxicity and reduced the G2/M phase arrest indicating that MR exhibits protection against DOX-induced toxicity. In NORT, DOX treatment significantly decreased the Recognition and discriminative indices (RI and DI) indicating DOX impairs episodic memory. Treatment with MR (1.26 and 1.52 g/kg) significantly protected against DOX-induced cognitive dysfunctions. DOX treatment also increased the brain oxidative stress and produced hepato, cardio, nephrotoxicity and myelosuppression. MR treatment ameliorated the DOX-induced toxicity. Conclusion: These results showed that MR pre-treatment could protect against post chemotherapy-induced cognitive dysfunction along with an overall reduction in chemotherapy-induced toxicity.

Original languageEnglish
Pages (from-to)S104-S111
JournalIndian Journal of Pharmaceutical Education and Research
Volume53
Issue number2
DOIs
Publication statusPublished - 01-04-2019

Fingerprint

Neuroprotective Agents
Doxorubicin
G2 Phase
Cell Division
Therapeutics
Cognitive Dysfunction
Drug Therapy
Cell Line
Episodic Memory
Cognition
Cell Survival
Cell Cycle
Oxidative Stress
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Gourishetti, Karthik ; Ghetia, Sawan ; Jacob, Ligin ; Mallik, Sanchari Basu ; Nayak, Pawan Ganesh ; Kishore, Anoop ; Nandakumar, Krishnadas ; Alnaseer, Sulaiman Mohammed ; Hussain, Shalam Mohamed. / Medhya rasayana restores memory function against doxorubicin-induced cognitive decline: Possibly by its neuroprotective effect. In: Indian Journal of Pharmaceutical Education and Research. 2019 ; Vol. 53, No. 2. pp. S104-S111.
@article{9eca5e5f759b49dc8a8b015776f6ce93,
title = "Medhya rasayana restores memory function against doxorubicin-induced cognitive decline: Possibly by its neuroprotective effect",
abstract = "Background: Medhya Rasayana (MR) is an ayurvedic formulation used to rejuvenate the intellectual functions. It was shown to improve the cognitive function in rats. Hence, the present study was designed to study the neuroprotective effect of MR against Doxorubicin (DOX)-induced cognitive deficits which usually occurs in long-term breast cancer survivors. Methods: The neuroprotective effect of MR was studied in-vitro using IMR-32 cell lines against DOX-induced toxicity while the protective effect of MR against DOX-induced cognitive dysfunction was evaluated in Novel object recognition task (NORT) assay in rats. Results: In IMR-32 cell line, DOX (100 nM) treatment reduced the cell viability and arrested the cell cycle at G2/M phase. Pre-treatment with MR significantly prevented the DOX-induced cytotoxicity and reduced the G2/M phase arrest indicating that MR exhibits protection against DOX-induced toxicity. In NORT, DOX treatment significantly decreased the Recognition and discriminative indices (RI and DI) indicating DOX impairs episodic memory. Treatment with MR (1.26 and 1.52 g/kg) significantly protected against DOX-induced cognitive dysfunctions. DOX treatment also increased the brain oxidative stress and produced hepato, cardio, nephrotoxicity and myelosuppression. MR treatment ameliorated the DOX-induced toxicity. Conclusion: These results showed that MR pre-treatment could protect against post chemotherapy-induced cognitive dysfunction along with an overall reduction in chemotherapy-induced toxicity.",
author = "Karthik Gourishetti and Sawan Ghetia and Ligin Jacob and Mallik, {Sanchari Basu} and Nayak, {Pawan Ganesh} and Anoop Kishore and Krishnadas Nandakumar and Alnaseer, {Sulaiman Mohammed} and Hussain, {Shalam Mohamed}",
year = "2019",
month = "4",
day = "1",
doi = "10.5530/ijper.53.2s.54",
language = "English",
volume = "53",
pages = "S104--S111",
journal = "Indian Journal of Pharmaceutical Education and Research",
issn = "0019-5464",
publisher = "Association of Pharmaceutical Teachers of India",
number = "2",

}

Medhya rasayana restores memory function against doxorubicin-induced cognitive decline: Possibly by its neuroprotective effect. / Gourishetti, Karthik; Ghetia, Sawan; Jacob, Ligin; Mallik, Sanchari Basu; Nayak, Pawan Ganesh; Kishore, Anoop; Nandakumar, Krishnadas; Alnaseer, Sulaiman Mohammed; Hussain, Shalam Mohamed.

In: Indian Journal of Pharmaceutical Education and Research, Vol. 53, No. 2, 01.04.2019, p. S104-S111.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Medhya rasayana restores memory function against doxorubicin-induced cognitive decline: Possibly by its neuroprotective effect

AU - Gourishetti, Karthik

AU - Ghetia, Sawan

AU - Jacob, Ligin

AU - Mallik, Sanchari Basu

AU - Nayak, Pawan Ganesh

AU - Kishore, Anoop

AU - Nandakumar, Krishnadas

AU - Alnaseer, Sulaiman Mohammed

AU - Hussain, Shalam Mohamed

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Medhya Rasayana (MR) is an ayurvedic formulation used to rejuvenate the intellectual functions. It was shown to improve the cognitive function in rats. Hence, the present study was designed to study the neuroprotective effect of MR against Doxorubicin (DOX)-induced cognitive deficits which usually occurs in long-term breast cancer survivors. Methods: The neuroprotective effect of MR was studied in-vitro using IMR-32 cell lines against DOX-induced toxicity while the protective effect of MR against DOX-induced cognitive dysfunction was evaluated in Novel object recognition task (NORT) assay in rats. Results: In IMR-32 cell line, DOX (100 nM) treatment reduced the cell viability and arrested the cell cycle at G2/M phase. Pre-treatment with MR significantly prevented the DOX-induced cytotoxicity and reduced the G2/M phase arrest indicating that MR exhibits protection against DOX-induced toxicity. In NORT, DOX treatment significantly decreased the Recognition and discriminative indices (RI and DI) indicating DOX impairs episodic memory. Treatment with MR (1.26 and 1.52 g/kg) significantly protected against DOX-induced cognitive dysfunctions. DOX treatment also increased the brain oxidative stress and produced hepato, cardio, nephrotoxicity and myelosuppression. MR treatment ameliorated the DOX-induced toxicity. Conclusion: These results showed that MR pre-treatment could protect against post chemotherapy-induced cognitive dysfunction along with an overall reduction in chemotherapy-induced toxicity.

AB - Background: Medhya Rasayana (MR) is an ayurvedic formulation used to rejuvenate the intellectual functions. It was shown to improve the cognitive function in rats. Hence, the present study was designed to study the neuroprotective effect of MR against Doxorubicin (DOX)-induced cognitive deficits which usually occurs in long-term breast cancer survivors. Methods: The neuroprotective effect of MR was studied in-vitro using IMR-32 cell lines against DOX-induced toxicity while the protective effect of MR against DOX-induced cognitive dysfunction was evaluated in Novel object recognition task (NORT) assay in rats. Results: In IMR-32 cell line, DOX (100 nM) treatment reduced the cell viability and arrested the cell cycle at G2/M phase. Pre-treatment with MR significantly prevented the DOX-induced cytotoxicity and reduced the G2/M phase arrest indicating that MR exhibits protection against DOX-induced toxicity. In NORT, DOX treatment significantly decreased the Recognition and discriminative indices (RI and DI) indicating DOX impairs episodic memory. Treatment with MR (1.26 and 1.52 g/kg) significantly protected against DOX-induced cognitive dysfunctions. DOX treatment also increased the brain oxidative stress and produced hepato, cardio, nephrotoxicity and myelosuppression. MR treatment ameliorated the DOX-induced toxicity. Conclusion: These results showed that MR pre-treatment could protect against post chemotherapy-induced cognitive dysfunction along with an overall reduction in chemotherapy-induced toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85068505477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068505477&partnerID=8YFLogxK

U2 - 10.5530/ijper.53.2s.54

DO - 10.5530/ijper.53.2s.54

M3 - Article

VL - 53

SP - S104-S111

JO - Indian Journal of Pharmaceutical Education and Research

JF - Indian Journal of Pharmaceutical Education and Research

SN - 0019-5464

IS - 2

ER -